In the last decades the pharmacological treatment of obsessive-compulsive disorder (OCD) has been significantly promoted by the effectiveness of selective serotonin (5-HT) reuptake inhibitors (SSRIs) and the subsequent development of the 5-HT hypothesis of OCD. However, since a large majority of patients (between 40% and 60 %) do not respond to SSRIs or strategies based on the modulation of the 5-HT system, it is now essential to search for other possible therapeutic targets.
Marazziti, D., Albert, U., Mucci, F., Piccinni, A. (2018). The glutamate and the immune systems: new targets for the pharmacological treatment of OCD. CURRENT MEDICINAL CHEMISTRY, 25(41), 5731-5738 [10.2174/0929867324666171108152035].
The glutamate and the immune systems: new targets for the pharmacological treatment of OCD
Albert, Umberto;
2018
Abstract
In the last decades the pharmacological treatment of obsessive-compulsive disorder (OCD) has been significantly promoted by the effectiveness of selective serotonin (5-HT) reuptake inhibitors (SSRIs) and the subsequent development of the 5-HT hypothesis of OCD. However, since a large majority of patients (between 40% and 60 %) do not respond to SSRIs or strategies based on the modulation of the 5-HT system, it is now essential to search for other possible therapeutic targets.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
